αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease

Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement

(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,620 · see citing works

A Mechanism for Regulating Pulmonary Inflammation and Fibrosis: The Integrin αvβ6 Binds and Activates Latent TGF β1

Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076 · see citing works

Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification

KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261 · see citing works

Histopathologic Variability in Usual and Nonspecific Interstitial Pneumonias

FLAHERTY, K. R., Travis, W. D., Colby, T. V., Toews, G. B., Kazerooni, E. A., Gross, B. H., Jain, A. K., Strawderman, R. L., Flint, A., Lynch, J. P., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2103074 · Cited by 666 · see citing works

Idiopathic Pulmonary Fibrosis

King, T. E., Schwarz, M. I., Brown, K. M., Tooze, J. A., Colby, T. V., Waldron, J. A., Flint, A., Thurlbeck, W. M., & Cherniack, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.6.2001056 · Cited by 629 · see citing works

MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis

Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E., Lindell, K. O., Cisneros, J., MacDonald, S. D., Pardo, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050093 · Cited by 582 · see citing works

Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK

Gribbin, J., Hubbard, R., Jeune, I. L., Smith, C. J. P., West, J., & Tata, L. J. (2006) · Thorax · doi:10.1136/thx.2006.062836 · Cited by 574 · see citing works

Molecular Targets in Pulmonary Fibrosis

Scotton, C. J., & Chambers, R. C. (2007) · CHEST Journal · doi:10.1378/chest.06-2568 · Cited by 533 · see citing works

The rising incidence of idiopathic pulmonary fibrosis in the UK

Navaratnam, V. V., Fleming, K. M., West, J., Smith, C. J. P., Jenkins, G. R., Fogarty, A., & Hubbard, R. (2011) · Thorax · doi:10.1136/thx.2010.148031 · Cited by 484 · see citing works

Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation

Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-805oc · Cited by 420 · see citing works

Comparative Study of KL-6, Surfactant Protein-A, Surfactant Protein-D, and Monocyte Chemoattractant Protein-1 as Serum Markers for Interstitial Lung Diseases

Ohnishi, H., Yokoyama, A., Kondo, K., Hamada, H., Abe, M., Nishimura, K., Hiwada, K., & Kohno, N. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.3.2107134 · Cited by 400 · see citing works

Clinical significance of histological classification of idiopathic interstitial pneumonia

Flaherty, K. R., Toews, G. B., Travis, W. D., Colby, T. V., Kazerooni, E. A., Gross, B. H., Jain, A. K., Strawderman, R. L., Paine, R., Flint, A., et al. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00182002 · Cited by 371 · see citing works

Gene Expression Profiles of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Konishi, K., Gibson, K. F., Lindell, K. O., Richards, T. J., Zhang, Y., Dhir, R., Bisceglia, M., Gilbert, S., Yousem, S. A., Song, J. W., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200810-1596oc · Cited by 334 · see citing works

Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis

Prasse, A., Probst, C., Bargagli, E., Zissel, G., Toews, G. B., Flaherty, K. R., Olschewski, M., Rottoli, P., & Müller–Quernheim, J. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1201oc · Cited by 329 · see citing works

Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment I

Walker, R. A. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02514.x · Cited by 319 · see citing works

Prevalence and prognosis of unclassifiable interstitial lung disease

Ryerson, C. J., Urbania, T. H., Richeldi, L., Mooney, J. J., Lee, J. S., Jones, K. D., Elicker, B. M., Koth, L. L., King, T. E., Wolters, P. J., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00131912 · Cited by 312 · see citing works

The Relationship between Individual Histologic Features and Disease Progression in Idiopathic Pulmonary Fibrosis

Nicholson, A. G., Fulford, L. G., Colby, T. V., du Bois, R. M., Hansell, D. M., & Wells, A. U. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2109039 · Cited by 300 · see citing works

Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis

DePianto, D. J., Chandriani, S. J., Abbas, A. R., Jia, G., N'Diaye, E. N., Caplazi, P., Kauder, S. E., Biswas, S., Karnik, S. K., Ha, C., et al. (2014) · Thorax · doi:10.1136/thoraxjnl-2013-204596 · Cited by 289 · see citing works

Inhibition of Integrin αvβ6, an Activator of Latent Transforming Growth Factor-β, Prevents Radiation-induced Lung Fibrosis

Puthawala, K., Hadjiangelis, N., Jacoby, S. C., Bayongan, E., Zhao, Z., Yang, Z., Devitt, M. L., Horan, G. S., Weinreb, P. H., Lukashev, M. E., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-806oc · Cited by 272 · see citing works

High short-term mortality following lung biopsy for usual interstitial pneumonia

Utz, J. P., Ryu, J. H., Douglas, W. W., Hartman, T. E., Tazelaar, H. D., Myers, J. L., Allen, M. S., & Schroeder, D. R. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.17201750 · Cited by 258 · see citing works

Lysophosphatidic Acid Induces αvβ6 Integrin-Mediated TGF-β Activation via the LPA2 Receptor and the Small G Protein Gαq

Xu, M. Y., Porte, J., Knox, A. J., Weinreb, P. H., Maher, T. M., Violette, S. M., McAnulty, R. J., Sheppard, D., & Jenkins, G. R. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080160 · Cited by 212 · see citing works

Mutations in the Surfactant Protein C Gene Associated With Interstitial Lung Disease

Nogee, L. M., Dunbar, A. E., Wert, S. E., Askin, F. B., Hamvas, A., & Whitsett, J. A. (2002) · CHEST Journal · doi:10.1378/chest.121.3_suppl.20s · Cited by 198 · see citing works

C-X-C Motif Chemokine 13 (CXCL13) is a Prognostic Biomarker of Idiopathic Pulmonary Fibrosis

Vuga, L. J., Tedrow, J. R., Pandit, K. V., Tan, J., Kass, D. J., Xue, J., Chandra, D., Leader, J. K., Gibson, K. F., Kaminski, N., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1592oc · Cited by 197 · see citing works

Molecular Phenotypes Distinguish Patients with Relatively Stable from Progressive Idiopathic Pulmonary Fibrosis (IPF)

Boon, K., Bailey, N., Yang, J., Steel, M. P., Groshong, S. D., Kervitsky, D. J., Brown, K. K., Schwarz, M. I., & Schwartz, D. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005134 · Cited by 183 · see citing works

Hepatocyte Growth Factor Gene Therapy and Angiotensin II Blockade Synergistically Attenuate Renal Interstitial Fibrosis in Mice

Yang, J., Dai, C., & Liu, Y. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000031827.16102.c1 · Cited by 153 · see citing works

Function-blocking Integrin αvβ6 Monoclonal Antibodies

Weinreb, P. H., Simon, K. J., Rayhorn, P., Yang, W. J., Leone, D. R., Dolinski, B. M., Pearse, B. R., Yokota, Y., Kawakatsu, H., Atakilit, A., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312103200 · Cited by 149 · see citing works

Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis.

Kuhn, C., & Mason, R. J. A. (1995) · Europe PMC (PubMed Central) · Cited by 123 · see citing works

A randomized, controlled trial comparing thoracoscopy and limited thoracotomy for lung biopsy in interstitial lung disease

Miller, J. D., Urschel, J. D., Cox, G., Olak, J., Young, J. E. M., Kay, J. M., & McDonald, E. (2000) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(00)01913-5 · Cited by 116 · see citing works

Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma

Fisher, E. R., Anderson, S., Dean, S., Dabbs, D. J., Fisher, B., Siderits, R. H., Pritchard, J., Pereira, T. C., Geyer, C. E., & Wolmark, N. (2004) · Cancer · doi:10.1002/cncr.20761 · Cited by 93 · see citing works

Preclinical SPECT/CT Imaging of αvβ6 Integrins for Molecular Stratification of Idiopathic Pulmonary Fibrosis

John, A. E., Luckett, J., Tatler, A. L., Awais, R. O., Desai, A., Habgood, A., Ludbrook, S. B., Blanchard, A. D., Perkins, A. C., Jenkins, G. R., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120592 · Cited by 93 · see citing works

Idiopathic pulmonary fibrosis: immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers.

(2012) · PubMed Central · Cited by 90 · see citing works

Efficacy of video assisted thoracoscopic lung biopsy: an historical comparison with open lung biopsy.

Carnochan, F. M., Walker, W. S. G., & Cameron, E. W. (1994) · Thorax · doi:10.1136/thx.49.4.361 · Cited by 82 · see citing works

Protein C Anticoagulant System in Patients with Interstitial Lung Disease

Kobayashi, H., Gabazza, E. C., Taguchi, O., Wada, H., Takeya, H., Nishioka, J., Yasui, H., Kobayashi, T., Hataji, O., Suzuki, K., et al. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.6.9709078 · Cited by 69 · see citing works

Defect of Pro-Hepatocyte Growth Factor Activation by Fibroblasts in Idiopathic Pulmonary Fibrosis

Marchand-Adam, S., Fabre, A., Mailleux, A., Marchal-Sommé, J., Quesnel, C., Kataoka, H., Aubier, M., Dehoux, M., Soler, P., & Crestani, B. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200507-1074oc · Cited by 61 · see citing works

Tenascin Immunoreactivity as a Prognostic Marker in Usual Interstitial Pneumonia

Kaarteenaho–Wiik, R., Tani, T. T., Sormunen, R. T., Soini, Y., Virtanen, I., & Pääkkö, P. K. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.154.2.8756830 · Cited by 60 · see citing works

Profusion of fibroblast foci in patients with idiopathic pulmonary fibrosis does not predict outcome

Hanak, V., Ryu, J. H., de Carvalho, É., LIMPER, A. H., Hartman, T. E., Decker, P. A., & Myers, J. L. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.01.012 · Cited by 46 · see citing works

Prognostic factors for idiopathic pulmonary fibrosis: clinical, physiologic, pathologic, and molecular aspects.

Lee, S. H., Shim, H. S., Cho, S. H., Kim, S. Y., Lee, S. K., Son, J. Y., Jung, J. Y., Kim, E. Y., Lim, J. E., Lee, K. J., et al. (2011) · PubMed · Cited by 42 · see citing works

Epithelial–mesenchymal transition in human lungs with usual interstitial pneumonia: Quantitative immunohistochemistry

Harada, T., Nabeshima, K., Hamasaki, M., Uesugi, N., Watanabe, K., & Iwasaki, H. (2009) · Pathology International · doi:10.1111/j.1440-1827.2009.02469.x · Cited by 42 · see citing works

Emerging therapeutic opportunities for integrin inhibitors

Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, G. R., & Hatley, R. J. D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00284-4 · Cited by 550 · see citing works

An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis

Jenkins, G. R., Moore, B. B., Chambers, R. C., Eickelberg, O., Königshoff, M., Kolb, M. R. J., Laurent, G. J., Nanthakumar, C. B., Olman, M. A., Pardo, A., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0096st · Cited by 446 · see citing works

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study

Maher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., Flynn, A., Molyneaux, P. L., Braybrooke, R., Divyateja, H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30430-7 · Cited by 271 · see citing works

The therapy of idiopathic pulmonary fibrosis: what is next?

Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N. C., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 266 · see citing works

Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history

Sgalla, G., Biffi, A., & Richeldi, L. (2015) · Respirology · doi:10.1111/resp.12683 · Cited by 173 · see citing works

Precision medicine advances in idiopathic pulmonary fibrosis

Karampitsakos, Τ., Juan-Guardela, B. M., Τzouvelekis, Α., & Herazo‐Maya, J. D. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104766 · Cited by 147 · see citing works

Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis

John, A. E., Graves, R. H., Pun, K. T., Vitulli, G., Forty, E. J., Mercer, P. F., Morrell, J. L., Barrett, J. W., Rogers, R. F., Hafeji, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18397-6 · Cited by 131 · see citing works

The extracellular matrix and mechanotransduction in pulmonary fibrosis

Deng, Z., Fear, M. W., Choi, Y. S., Wood, F. M., Allahham, A., Mutsaers, S. E., & Prêle, C. M. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105802 · Cited by 122 · see citing works

Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis

Kimura, R. H., Wang, L., Shen, B., Huo, L., Tummers, W. S. F. J., Filipp, F. V., Guo, H. H., Haywood, T., Abou‐Elkacem, L., Baratto, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11863-w · Cited by 120 · see citing works

Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis

Bowman, W. S., Newton, C. A., Linderholm, A., Neely, M. L., Pugashetti, J. V., Kaul, B., Vo, V., Echt, G., Leon, W., Shah, R., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00503-8 · Cited by 111 · see citing works

Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF

Decaris, M. L., Schaub, J. R., Chen, C., Cha, J., Lee, G. G., Rexhepaj, M., Ho, S. S., Rao, V., Marlow, M. M., Kotak, P., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01863-0 · Cited by 94 · see citing works

Recent advances in understanding idiopathic pulmonary fibrosis

Daccord, C., & Maher, T. M. (2016) · F1000Research · doi:10.12688/f1000research.8209.1 · Cited by 88 · see citing works

Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis

Shea, B. S., Probst, C. K., Brazee, P. L., Rotile, N. J., Blasi, F., Weinreb, P. H., Black, K. E., Sosnovik, D. E., Cott, E. M. V., Violette, S. M., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.86608 · Cited by 85 · see citing works

Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial

Lancaster, L., Cottin, V., Ramaswamy, M., Wuyts, W. A., Jenkins, R. G., Scholand, M. B., Kreuter, M., Valenzuela, C., Ryerson, C. J., Goldin, J., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202403-0636oc · Cited by 80 · see citing works

Integrins as a drug target in liver fibrosis

Rahman, S. R., Roper, J. A., Grove, J. I., Aithal, G. P., Pun, K. T., & Bennett, A. J. (2022) · Liver International · doi:10.1111/liv.15157 · Cited by 74 · see citing works

A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor

Maher, T. M., Simpson, J. K., Porter, J. C., Wilson, F. J., Chan, R. H., Eames, R., Cui, Y., Siederer, S. K., Parry, S., Kenny, J. D., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01339-7 · Cited by 73 · see citing works

Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis

Oldham, J. M., Huang, Y., Bose, S., Ma, S.-F., Kim, J. S., Schwab, A., Ting, C., Mou, K., Lee, C. T., Adegunsoye, A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202301-0117oc · Cited by 72 · see citing works

Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis

Fabrellas, E. F., Sánchez, R. P., Abad, C. S., & Samper, G. J. (2018) · Medical Sciences · doi:10.3390/medsci6020051 · Cited by 69 · see citing works

Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis

Brownell, R., Kaminski, N., Woodruff, P. G., Bradford, W. Z., Richeldi, L., Martínez, F. J., & Collard, H. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0169ci · Cited by 67 · see citing works

Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option

Korfei, M., Mahavadi, P., & Guenther, A. (2022) · Cells · doi:10.3390/cells11101626 · Cited by 64 · see citing works

Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants

Maden, C. H., Fairman, D., Chalker, M., Costa, M. J., Fahy, W. A., Garman, N., Lukey, P. T., Mant, T., Parry, S., Simpson, J. K., et al. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2435-3 · Cited by 65 · see citing works

Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)

Lukey, P. T., Coello, C. S., Gunn, R. N., Parker, C. A., Wilson, F. J., Saleem, A., Garman, N., Costa, M. J., Kendrick, S. F. W., Onega, M., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04586-z · Cited by 64 · see citing works

3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs

Surolia, R., Li, F. J., Wang, Z., Li, H., Liu, G., Zhou, Y., Luckhardt, T., Bae, S., Liu, R.-M., Rangarajan, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91377 · Cited by 63 · see citing works

Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies

Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57 · see citing works

Amplification of TGFβ Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis

Tatler, A. L., Goodwin, A. T., Gbolahan, O., Saini, G., Porte, J., John, A. E., Clifford, R. L., Violette, S. M., Weinreb, P. H., Parfrey, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158047 · Cited by 50 · see citing works

A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis

Roach, K. M., Sutcliffe, A., Matthews, L., Elliott, G., Newby, C., Amrani, Y., & Bradding, P. H. (2018) · Scientific Reports · doi:10.1038/s41598-017-18555-9 · Cited by 49 · see citing works

De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8

Roy, A., Shi, L., Chang, A., Dong, X., Fernandez, A. N., Kraft, J. C., Li, J., Le, V. Q., Winegar, R. V., Cherf, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41272-z · Cited by 50 · see citing works

Novel drug targets for idiopathic pulmonary fibrosis

Sgalla, G., Cocconcelli, E., Tonelli, R., & Richeldi, L. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1152186 · Cited by 42 · see citing works

Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis

Hasan, M., Paul, N. C., Paul, S. K., Saikat, A. S. M., Akter, H., Mandal, M., & Lee, S. (2022) · Molecules · doi:10.3390/molecules27051481 · Cited by 42 · see citing works

Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis

Inchingolo, R., Varone, F., Sgalla, G., & Richeldi, L. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1553620 · Cited by 37 · see citing works

COVID-19 and acute exacerbation of interstitial lung disease

Kondoh, Y., Kataoka, K., Ando, M., Awaya, Y., Ichikado, K., Kataoka, M., Komase, Y., Mineshita, M., Ohno, Y., Okamoto, H., et al. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.06.007 · Cited by 34 · see citing works

Molecular Endotyping of Pulmonary Fibrosis

Goodwin, A. T., & Jenkins, G. R. (2015) · CHEST Journal · doi:10.1378/chest.15-1511 · Cited by 33 · see citing works

Cell adhesion molecules in fibrotic diseases

Hu, Q., Saleem, K., Pandey, J., Charania, A. N., Zhou, Y., & He, C. (2023) · Biomedicines · doi:10.3390/biomedicines11071995 · Cited by 32 · see citing works

Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin αvβ6 Expression

Tatler, A. L., Habgood, A., Porte, J., John, A. E., Stavrou, A., Hodge, E., Kerama-Likoko, C., Violette, S. M., Weinreb, P. H., Knox, A. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.692368 · Cited by 32 · see citing works

The Dawn of Precision Medicine in Fibrotic Interstitial Lung Disease

Karampitsakos, Τ., Tourki, B., & Herazo‐Maya, J. D. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.10.042 · Cited by 31 · see citing works

A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of18F-FB-A20FMDV2 for Imaging the Integrin αvβ6

Keat, N., Kenny, J. D., Chen, K., Onega, M., Garman, N., Slack, R. J., Parker, C. A., Lumbers, R. T., Hallett, W., Saleem, A., et al. (2018) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.117.203547 · Cited by 31 · see citing works

Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options

Hewitt, R. J., & Maher, T. M. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00647-y · Cited by 31 · see citing works

STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis–associated Interstitial Lung Disease

Khanna, D., Tashkin, D. P., Wells, A. U., Seibold, J. R., Wax, S. D., Vazquez‐Mateo, C., Fleuranceau-Morel, P., Damian, D., & Denton, C. P. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.191365 · Cited by 28 · see citing works

Evolution and treatment of idiopathic pulmonary fibrosis

Torrisi, S. E., Kahn, N. C., Vancheri, C., & Kreuter, M. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104025 · Cited by 27 · see citing works

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis

Aryal, S., & Nathan, S. D. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1471465 · Cited by 26 · see citing works

Dual αvβ6 and αvβ1 Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial

Montesi, S. B., Cosgrove, G. P., Turner, S., Zhou, I. Y., Efthimiou, N., Šušnjar, A., Catana, C., Fromson, C., Clark, A., Decaris, M. L., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202410-1934oc · Cited by 25 · see citing works

Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies

Magnini, D., Montemurro, G., Iovene, B., Tagliaboschi, L., Gerardi, R. E., Greco, E. L., Bruni, T., Fabbrizzi, A., Lombardi, F., & Richeldi, L. (2017) · Respiration · doi:10.1159/000475780 · Cited by 25 · see citing works

Goldilocks and the Three Trials: Clinical Trials Targeting the αvβ6 Integrin in Idiopathic Pulmonary Fibrosis

Sime, P. J., & Jenkins, G. R. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202208-1579ed · Cited by 24 · see citing works

Advances in idiopathic pulmonary fibrosis diagnosis and treatment

Liu, H., Shen, J., & He, C. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.02.001 · Cited by 21 · see citing works

Pharmacological targeting of ECM homeostasis, fibroblast activation and invasion for the treatment of pulmonary fibrosis

Tomos, I. P., Kanellopoulou, P., Nastos, D., & Aidinis, V. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2471579 · Cited by 19 · see citing works

The IL-33:ST2 axis is unlikely to play a central fibrogenic role in idiopathic pulmonary fibrosis

Stephenson, K. E., Porte, J., Kelly, A., Wallace, W. A., Huntington, C. E. C., Overed-Sayer, C. L., Cohen, E. S., Jenkins, G. R., & John, A. E. (2023) · Respiratory Research · doi:10.1186/s12931-023-02334-4 · Cited by 20 · see citing works

Sex-specific differences in primary neonatal murine lung fibroblasts exposed to hyperoxia in vitro: implications for bronchopulmonary dysplasia

Balaji, S., Dong, X., Li, H., Zhang, Y., Steen, E. H., & Lingappan, K. (2018) · Physiological Genomics · doi:10.1152/physiolgenomics.00075.2018 · Cited by 20 · see citing works

Antibody-based therapies for idiopathic pulmonary fibrosis

Sgalla, G., Flore, M., Siciliano, M., & Richeldi, L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1735346 · Cited by 20 · see citing works

Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis

Wang, Q., Xie, Z., Wan, N., Yang, L., Jin, Z., Jin, F., Huang, Z., Chen, M., Wang, H., & Feng, J. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002171 · Cited by 19 · see citing works

COVID-19 and interstitial lung diseases: A multifaceted look at the relationship between the two diseases

Fukihara, J., & Kondoh, Y. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.05.007 · Cited by 22 · see citing works

New treatment directions for IPF: current status of ongoing and upcoming clinical trials

Macagno, F., Varone, F., Leone, P. M., Mari, P., Panico, L., Berardini, L., & Richeldi, L. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1335601 · Cited by 18 · see citing works

Bexotegrast Shows Dose-Dependent Integrin αvβ6 Receptor Occupancy in Lungs of Participants with Idiopathic Pulmonary Fibrosis: A Phase 2, Open-Label Clinical Trial

Mooney, J. J., Jacobs, S. S., Lefebvre, E. A., Cosgrove, G. P., Clark, A., Turner, S., Decaris, M. L., Barnes, C. N., Jurek, M., Williams, B., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202409-969oc · Cited by 17 · see citing works

Mini review of first-in-human integrin αvβ6 PET tracers

Kimura, R. H., Iagaru, A. H., & Guo, H. H. (2023) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2023.1271208 · Cited by 17 · see citing works

Soluble ITGaM and ITGb2 Integrin Subunits Are Involved in Long-Term Pulmonary Complications after COVID-19 Infection

Siekacz, K., Kumor‐Kisielewska, A., Miłkowska-Dymanowska, J., Pietrusińska, M., Bartczak, K. T., Majewski, S., Stańczyk, A., Piotrowski, W. J., & Białas, A. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010342 · Cited by 16 · see citing works

Investigational drugs for idiopathic pulmonary fibrosis

Varone, F., Montemurro, G., Macagno, F., Calvello, M., Conte, E. G., Intini, E., Iovene, B., Leone, P. M., Mari, P., & Richeldi, L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1364361 · Cited by 15 · see citing works

Ligand-bound integrin αvβ6 internalisation and trafficking

Meecham, A., Cutmore, L. C., Protopapa, P., Rigby, L. G., & Marshall, J. F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.920303 · Cited by 15 · see citing works

Small-animal SPECT/CT imaging of cancer xenografts and pulmonary fibrosis using a 99mTc-labeled integrin αvβ6-targeting cyclic peptide with improved in vivo stability

Liu, H., Gao, L., Yu, X., Zhong, L., Shi, J., Jia, B., Li, N., Liu, Z., & Wang, F. (2018) · Biophysics Reports · doi:10.1007/s41048-018-0071-1 · Cited by 15 · see citing works

Late‐Stage Functionalization by Chan–Lam Amination: Rapid Access to Potent and Selective Integrin Inhibitors

Robinson, H., Oatley, S. A., Rowedder, J. E., Slade, P., Macdonald, S. J. F., Argent, S. P., Hirst, J. D., McInally, T., & Moody, C. J. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202001059 · Cited by 15 · see citing works

Harnessing the power of foot-and-mouth-disease virus for targeting integrin alpha-v beta-6 for the therapy of cancer

Meecham, A., & Marshall, J. F. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1878143 · Cited by 15 · see citing works

Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions

Eriksson, O., & Velikyan, I. (2023) · Pharmaceuticals · doi:10.3390/ph16111540 · Cited by 14 · see citing works

Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts

Maddali, M. V., Moore, A. R., Sinha, P., Newton, C. A., Kim, J. S., Adegunsoye, A., Ma, S., Strek, M. E., Chen, C., Linderholm, A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202402-0339oc · Cited by 14 · see citing works

Catch your breath: The protective role of the angiotensin AT2 receptor for the treatment of idiopathic pulmonary fibrosis

Young, O. N., Bourke, J. E., & Widdop, R. E. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115839 · Cited by 14 · see citing works

Antifibrotic Drugs against Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis Induced by COVID-19: Therapeutic Approaches and Potential Diagnostic Biomarkers

Perez-Favila, A., Veloz, I. G., Hernandez-Marquez, L. S., Gutierrez-Vela, E. F., Flores‐Morales, V., & Martínez‐Fierro, M. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031562 · Cited by 13 · see citing works

Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic disease

Wilkinson, A. L., John, A. E., Barrett, J. W., Gower, E., Morrison, V. S., Man, Y., Pun, K., Roper, J. A., Luckett, J., Borthwick, L. A., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174618 · Cited by 13 · see citing works

Biomarkers Unveil Insights into Pathology of Transitional Epithelial States in Pulmonary Fibrosis

Ting, C., Konopka, K. E., Benedeck, R. E., Riches, D. W. H., Redente, E. F., Oldham, J. M., & Zemans, R. L. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202310-1839le · Cited by 12 · see citing works

Interleukin-11: A central integrative hub driving pathological progression from pulmonary inflammation and fibrosis to cancer

Yu, J., Qi, J., Kong, X., & Feng, Y. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107966 · Cited by 11 · see citing works

Neonatal Lung Disease: Mechanisms Driving Sex Differences

Lingappan, K., Hayward-Piatkovskyi, B., & Gleghorn, J. P. (2021) · Physiology in health and disease · doi:10.1007/978-3-030-63549-7_5 · Cited by 11 · see citing works

αVβ6 Integrin: An Intriguing Target for COVID‐19 and Related Diseases

Bugatti, K. (2021) · ChemBioChem · doi:10.1002/cbic.202100209 · Cited by 10 · see citing works

Mechanisms on How Matricellular Microenvironments Sustain Idiopathic Pulmonary Fibrosis

Jones, N., Rahar, B., Bernau, K., Schulte, J. J., Campagnola, P. J., & Brasier, A. R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115393 · Cited by 8 · see citing works

Clinical Trials in IPF: What Are the Best Endpoints?

Spagnolo, P., Cocconcelli, E., & Cottin, V. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_19 · Cited by 8 · see citing works

Preclinical evaluation of [18F]FB-A20FMDV2 as a selective marker for measuring αVβ6 integrin occupancy using positron emission tomography in rodent lung

Onega, M., Parker, C. A., Coello, C. S., Rizzo, G., Keat, N., Ramada‐Magalhaes, J., Moz, S., Tang, S.-P., Plisson, C., Wells, L. A., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04653-5 · Cited by 8 · see citing works

Overview of positron emission tomography in functional imaging of the lungs for diffuse lung diseases

Gulhane, A. V., & Chen, D. L. (2021) · British Journal of Radiology · doi:10.1259/bjr.20210824 · Cited by 8 · see citing works

Exploring the Role of Biomarkers Associated with Alveolar Damage and Dysfunction in Idiopathic Pulmonary Fibrosis—A Systematic Review

Zamfir, A.-S., Zabara, M., Arcana, R. I., Cernomaz, A. T., Zabara-Antal, A., Marcu, D. T. M., Trofor, A. C., Zamfir, C. L., & Crișan-Dabija, R. A. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111607 · Cited by 7 · see citing works

Wilms Tumor 1-Driven Fibroblast Activation and Subpleural Thickening in Idiopathic Pulmonary Fibrosis

Gajjala, P. R., Singh, P., Odayar, V., Ediga, H. H., McCormack, F. X., & Madala, S. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032850 · Cited by 7 · see citing works

New targets in idiopathic pulmonary fibrosis: from inflammation and immunity to remodeling and repair

Froidure, A., Joannes, A., Mailleux, A., & Crestani, B. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1171140 · Cited by 7 · see citing works

Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial

Wuyts, W. A., LANCASTER, L. H., Maher, T. M., Ryerson, C. J., Kreuter, M., Corte, T. J., Valenzuela, C., Barnes, C. N., Lefebvre, E. A., Cosgrove, G. P., et al. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002937 · Cited by 5 · see citing works

Using Integrin αvβ6-Targeted Positron Emission Tomography Imaging to Longitudinally Monitor Radiation-Induced Pulmonary Fibrosis In Vivo

Lo, W. C. Y., Boas, C. W. V., Huynh, T. T., Klaas, A., Grogan, F., Strong, L., Samson, P. P., Robinson, C. G., Rogers, B. E., & Bergom, C. R. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.08.034 · Cited by 5 · see citing works

[68Ga]Ga-Trivehexin PET/CT imaging of integrin-αvβ6 expression in concomitant mucinous lung adenocarcinoma and idiopathic pulmonary fibrosis

Wu, H., Li, L., Xiao, Z., Chen, Q., Li, C., & He, Y. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07146-w · Cited by 5 · see citing works

Biomarkers in Idiopathic Pulmonary Fibrosis

Stankovic, S. D., Stjepanović, M., & Ašanin, M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100042 · Cited by 5 · see citing works

Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?

Inchingolo, R., Condoluci, C., Smargiassi, A., Mastrobattista, A., Boccabella, C., Comes, A., Golfi, N., & Richeldi, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1383382 · Cited by 5 · see citing works

Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient

Jones, M. G., Walsh, S. L. F., Jones, K. D., & Richeldi, L. (2016) · European Respiratory Journal · doi:10.1183/13993003.00265-2016 · Cited by 4 · see citing works

AN INTEGRIN RENAISSANCE: RECENT PROGRESS OF INTEGRIN MODULATORS IN THE CLINIC

Finkelstein, D. S., & Machajewski, T. D. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch08 · Cited by 3 · see citing works

Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease

Perrotta, F., Zamparelli, S. S., D’Agnano, V., Montella, A., Fomez, R., Pagliaro, R., Schiattarella, A., Cazzola, M., Bianco, A., & Mariniello, D. F. (2024) · Biomedicines · doi:10.3390/biomedicines12071384 · Cited by 4 · see citing works

Long COVID and Lung Involvement: A One-Year Longitudinal, Real-Life Study

Stefania, M. N., Toma, C., Bondor, C. I., Maria, R. V., Petrariu, F. D., & Man, M. A. (2025) · Medicina · doi:10.3390/medicina61020304 · Cited by 3 · see citing works

Pharmacologic Treatment of IPF

Smargiassi, A., Pasciuto, G., Conte, E. G., Andreani, M., Marra, R., & Richeldi, L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_13 · Cited by 3 · see citing works

Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis

Schott, C. A., Mohning, M. P., & Cooley, J. C. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2651-1937 · Cited by 2 · see citing works

A framework for translational research in interstitial lung disease (ILD) using bronchoalveolar lavage (BAL)

Mawer, C. M., Stanel, S. C., Ward, E. M., Smith, D. J. F., Hull, R. C., & Mehta, P. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2675640 · Cited by 2 · see citing works

Histopathology and cryobiopsy

Poletti, V. E., Tomassetti, S., Ravaglia, C., Dubini, A., Piciucchi, S., Cavazza, A., & Chilosi, M. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005015 · Cited by 2 · see citing works

Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis

Pasciuto, G., Inchingolo, R., Condoluci, C., Magnini, D., Iovene, B., & Richeldi, L. (2018) · Current Pulmonology Reports · doi:10.1007/s13665-018-0209-0 · Cited by 2 · see citing works

Novel drug targets in idiopathic pulmonary fibrosis

Calvello, M., Flore, M. C., & Richeldi, L. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1590196 · Cited by 2 · see citing works

Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?

Soskis, A., & Hallowell, R. W. (2021) · Respiration · doi:10.1159/000515607 · Cited by 2 · see citing works

PET Molecular Imaging and Theranostics in Lung Diseases

Assadi, M., Juweid, M., Jonigk, D. D., Spillner, J. W., Rayyan, Y. M., Jarraya, H., Mottaghy, F. M., & Dweik, R. A. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.03.025 · Cited by 1 · see citing works

Biomarkers in interstitial lung disease: moving towards composite indexes and multimarkers?

Ask, K., Hambly, N., & Kolb, M. R. J. (2015) · Current Pulmonology Reports · doi:10.1007/s13665-015-0123-7 · Cited by 1 · see citing works

Targeting the αv Integrins in Fibroproliferative Disease

Nanthakumar, C. B., Hatley, R. J. D., & Slack, R. J. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015783-00037 · Cited by 1 · see citing works

PDF 23 220 2022 MOST READ ARTICLES Examining Visfatin As a New Sarcoidosis Biomarker Tanrıverdi et al. Patients with Large-Cell Neuroendocrine Carcinoma Çırak et al. Asthma, Preoperative Risk Assessment Erdoğan et al. HIGHLY CITED ARTICLES Chronic Pulmonary Diseases and COVID-19 By: Edis, EC Turkish Thoracic Society Experts Consensus Report: Recommendations for Pulmonary Function Tests During and After COVID 19 Pandemic By: Gemicioglu, B; Borekci, S; Dilektasli, AG; et al. Health Hazards and Complications Associated with Electronic Cigarettes: A Review By: Gulsen, A and Uslu, B Validity and Reliability of the Turkish Version of the London Chest Activity of Daily Living Scale in Obstructive Lung Diseases By: Saka, S; Savci, S; Kutukcu, EC; et al. Which Screening Questionnaire is Best for Predicting Obstructive Sleep Apnea in the Sleep Clinic Population Considering Age, Gender, and Comorbidities? By: Arslan, BO; Hosgor, ZZU and Orman, MN Prevalence of Zinc Deficiency and the Effect of Zinc Supplementation on the Prevention of Acute Respiratory Infections By: Khera, D; Singh, S; Purohit, P; et al. Pulmonary Embolism in Covid-19: Coagulation Parameters, Close Monitoring to Prevent? By: Annunziata, A; Imitazione, P; Polistina, GE; et al. Self-Management Training in Chronic Obstructive Lung Disease Improves the Quality of Life By: Ozturk, BO; Alpaydin, AO; Ozalevli, S; et al. Evidence Based Treatment of SARS-CoV2: A Narrative Review By: Agrawal, S; Gupta, N and Goel, AD What We Learned about COVID-19 So Far? Notes from Underground By: Akyil, FT; Karadogan, D; Gurkan, CG; et al. Home Turkish Thoracic Society Early... Review Turkish Thoracic Society Early Career Members Task Force Group’s Virtual Congress Notes: European Respiratory Society International Congress 2020

Kızılırmak, D., Karadoğan, D., Yıldırım, H., Akyıl, F. T., Eyüboğlu, T. Ş., Emiralioğlu, N., Sertçelik, Ü. Ö., Günaydın, F. E., Ataoğlu, Ö., Oguz, M. S., et al. (2022) · Turkish Thoracic Journal · doi:10.5152/turkthoracj.2022.21081 · Cited by 1 · see citing works

Key ongoing issues in trial design

Jones, M. G., & Richeldi, L. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006515

Current concepts of idiopathic pulmonary fibrosis: focus on biomarkers

Anaev, E. K. (2017) · PULMONOLOGIYA · doi:10.18093/0869-0189-2017-27-1-56-64 · Cited by 1 · see citing works

Reply to Althuwaybi et al. : Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?

Chaudhuri, N., George, P. M., Kreuter, M., Molina‐Molina, M., Rivera‐Ortega, P., Stella, G. M., Stewart, I. D., Spencer, L. G., Wells, A. U., & Jenkins, G. R. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202011-4146le

INTEGRIS-IPF: A New Hope for Tomorrow

Wang, F., Zhu, M., & Luo, F. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202407-1295ed

Structural and Functional Characterization of Protein Adhesins and Pili in Mycobacterium tuberculosis

Farnia, P., Velayati, A. A., Ghanavi, J., & Farnia, P. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-96883-9_8

S66 Targeted in Vivo Imaging of the αvβ6 Integrin in Mice with Bleomycin-Induced Lung Fibrosis

John, A. E., Luckett, J., Awas, R., Habgood, A., Ludbrook, S. B., Blanchard, A. D., Perkins, A. C., Jenkins, G. R., & Marshall, J. F. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-202678.072 · Cited by 4 · see citing works

Preclinical SPECT/CT Imaging of αvβ6 Integrins for Molecular Stratification of Idiopathic Pulmonary Fibrosis

John, A. E., Luckett, J., Tatler, A. L., Awais, R. O., Desai, A., Habgood, A., Ludbrook, S. B., Blanchard, A. D., Perkins, A. C., Jenkins, G. R., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120592 · Cited by 93 · see citing works

The fibroblast activation protein alpha as a biomarker of pulmonary fibrosis

Lavis, P., Garabet, A., Cardozo, A. K., & Bondue, B. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1393778 · Cited by 16 · see citing works

Late Breaking Abstract - Circulating ITGB6 levels are elevated in patients with IPF and reduced following lung transplant

Decaris, M. L., Budi, E. H., Kotak, P., Jacobs, S. S., Desai, T., & Turner, S. (2023) · European Respiratory Journal · doi:10.1183/13993003.congress-2023.pa2969

Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosis

Bellani, S., Molyneaux, P. L., Maher, T. M., & Spagnolo, P. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2375375 · Cited by 15 · see citing works